Inmolecule Nanotech, S.A.
MLINA | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- ES0105908000
- LEI:
- 959800F0D3TQYVTXW034
- Country:
- Spain
- Address:
- N/A
- Website:
- https://www.inmolecule.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inmolecule Nanotech, S.A. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Inmolecule Nanotech, S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inmolecule Nanotech, S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
Sweden
STABL
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
South Korea
052020
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
Japan
4599
Develops regenerative antibodies modulating the Wnt pathway to repair tissues and restore organs.
United States of America
SRZN
United States of America
SRZN
AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.
South Korea
226330
South Korea
226330
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America
TNGX
United States of America
TNGX
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
United States of America
TSHA
United States of America
TSHA
Developing biologic therapies that modulate GPCRs for diseases with unmet needs.
United States of America
TECX
United States of America
TECX
Developing an oral small molecule to reverse aging and treat age-related diseases.
United States of America
TELO
United States of America
TELO
Clinical-stage oncology company developing oral small molecule therapeutics to treat cancer.
United States of America
TPST
United States of America
TPST